US › Healthcare

Entera Bio Ltd (ENTX)

US · Healthcare · Biotechnology

$2.87-3.04%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.5M
Profit YoY
-36.5%
EPS
$-0.07
EPS estimate
$-0.08

EPS came in at -0.07 against a street estimate of -0.08 — a beat of 12.5%.

Key statistics

Market cap
$147.4M
Forward P/E
0.0
P/B
13.66
Book value
$0.23
EPS (TTM)
$-0.26
52-week high
$4.20
52-week low
$0.91
50-day MA
$1.68
200-day MA
$1.70
Beta
1.43

Analyst view

Analysts rate Entera Bio Ltd a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.00.

Shareholding

Insiders
6.85%
Institutions
4.57%

Largest institutional holders

FundStake
Knoll Capital Management LP11.93%
Renaissance Technologies Corp0.96%
Parkman Healthcare Partners LLC0.59%
Citadel Advisors Llc0.50%
Seven Fleet Capital Management LP0.42%
Marshall Wace Asset Management Ltd0.40%
Northern Trust Corp0.30%
XTX Topco Ltd0.27%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Entera Bio Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.